|
|
 |
|
Viewing report
|
|
|
|
Watson Pharmaceuticals Inc.: PharmaVitae Profile
Datamonitor, Dec 2010, Pages: 62
Introduction
This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Watson's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Watson over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Watson's performance against key rivals in the prescription pharmaceutical sector
- Analyze how the acquisition of Arrow Pharmaceuticals has provided Watson with a much enhanced geographic footprint
- Assess how Watson will compete in an increasingly competitive generics market with enhanced specialist players and an increased Big Pharma presence
Customers who bought this item also bought
Mylan Inc.: PharmaVitae Profile
Teva Pharma. Industries Ltd: PharmaVitae Profile
Cephalon Inc.: PharmaVitae Profile
Sandoz International GmbH: PharmaVitae Profile
CSL Limited: PharmaVitae Profile
King Pharmaceuticals Inc.: PharmaVitae Profile
UCB S.A.: PharmaVitae Profile
Forest Laboratories Inc.: PharmaVitae Profile
Baxter International Inc.: PharmaVitae Profile
Boehringer Ingelheim GmbH: PharmaVitae Profile
|
|
|
|
